Cancer Genetics, Inc. engages in the development, commercialization, and sale of molecular and biomarker-based tests and services. Through its Select One Clinical Trials program, the firm provides a range of clinical trial services for both oncology and non-oncology genetic testing such as bioinformatics, biomaker solutions, biorepository solutions, consulting, cytogenetics testing, nucleic acid extraction and purification, flow cytometry, Focus::NGS Panel, gene expression analyses, genotyping, and pharmacogenomics. The company was founded by Raju S. K. Chaganti on April 8, 1999 and is headquartered in Rutherford, NJ.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CGIX
Previous Symbol
CUSIPN/A
Phone201-528-9200
Debt
Debt-to-Equity Ratio0.05
Current Ratio0.46
Quick Ratio0.46
Price-To-Earnings
Trailing P/E Ratio-0.26
Forward P/E Ratio-0.34
P/E GrowthN/A
Sales & Book Value
Annual Sales$29.12 million
Price / Sales0.19
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.97 per share
Price / Book0.21
Profitability
EPS (Most Recent Fiscal Year)($0.79)
Net Income$-20,880,000.00
Net Margins-87.08%
Return on Equity-121.10%
Return on Assets-49.36%
Miscellaneous
Employees245
Outstanding Shares27,750,000
Market Cap$5.99 million
OptionableOptionable
Cancer Genetics (NASDAQ:CGIX) Frequently Asked Questions
What is Cancer Genetics' stock symbol?
Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."
How were Cancer Genetics' earnings last quarter?
Cancer Genetics Inc (NASDAQ:CGIX) released its quarterly earnings data on Monday, November, 19th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.07. The medical research company had revenue of $5.94 million for the quarter, compared to analyst estimates of $8.09 million. Cancer Genetics had a negative return on equity of 121.10% and a negative net margin of 87.08%. View Cancer Genetics' Earnings History.
When is Cancer Genetics' next earnings date?
What price target have analysts set for CGIX?
3 brokers have issued 1-year target prices for Cancer Genetics' stock. Their predictions range from $3.00 to $6.00. On average, they anticipate Cancer Genetics' stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 2,150.0% from the stock's current price. View Analyst Price Targets for Cancer Genetics.
What is the consensus analysts' recommendation for Cancer Genetics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cancer Genetics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cancer Genetics.
What are Wall Street analysts saying about Cancer Genetics stock?
Here are some recent quotes from research analysts about Cancer Genetics stock:
- 1. Maxim Group analysts commented, "Cancer Genetics (CGI) reported 3Q18 with revenues of $5.9M, down 16% sequentially from $7.0M in 2Q18. The company also saw a reduced gross margin of 22% compared to 31% in the prior quarter. Operating Expenses were ~$9.3M, this includes $2.3M in costs from the ongoing restructuring plan and the NovellusDx merger. These factors led to a net loss of ($8.5M). The company reported a cash balance of $1.2M. Our focus on CGI remains implementing the restructuring program to try to position the company to return to growth across the clinical, biopharma and discovery services. We also remain concerned regarding capital needs, which CGI is working to address. The NovellusDx merger, which is on track to close in early 2019, is expected to bring in an additional $10M through an equity investment. More details are below; maintain Hold." (11/20/2018)
- 2. According to Zacks Investment Research, "Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey. " (7/3/2018)
Has Cancer Genetics been receiving favorable news coverage?
News coverage about CGIX stock has been trending somewhat positive on Tuesday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cancer Genetics earned a news impact score of 1.1 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days.
Who are some of Cancer Genetics' key competitors?
Who are Cancer Genetics' key executives?
Cancer Genetics' management team includes the folowing people:
- John A. Roberts, President & Chief Executive Officer
- Narasimha Marella, Vice President-Operations
- Ehab Elkhouly, VP-Clinical Affairs & Site Operations
- Weiyi Chen, Director-Molecular Diagnostics
- Pal Singh-Kahlon, Cytogenetics Director
Who are Cancer Genetics' major shareholders?
Cancer Genetics' stock is owned by many different of institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (4.64%), Renaissance Technologies LLC (2.43%), Stonepine Capital Management LLC (2.21%) and Vanguard Group Inc. (1.92%). Company insiders that own Cancer Genetics stock include Geoffrey E Harris, Igor Gitelman, John A Roberts and John Pappajohn. View Institutional Ownership Trends for Cancer Genetics.
Which major investors are selling Cancer Genetics stock?
Which major investors are buying Cancer Genetics stock?
CGIX stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Perkins Capital Management Inc. and Renaissance Technologies LLC. Company insiders that have bought Cancer Genetics stock in the last two years include Geoffrey E Harris, Igor Gitelman, John A Roberts and John Pappajohn. View Insider Buying and Selling for Cancer Genetics.
How do I buy shares of Cancer Genetics?
Shares of CGIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cancer Genetics' stock price today?
One share of CGIX stock can currently be purchased for approximately $0.20.
How big of a company is Cancer Genetics?
Cancer Genetics has a market capitalization of $5.99 million and generates $29.12 million in revenue each year. The medical research company earns $-20,880,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Cancer Genetics employs 245 workers across the globe.
What is Cancer Genetics' official website?
How can I contact Cancer Genetics?
Cancer Genetics' mailing address is 201 ROUTE 17 NORTH 2ND FLOOR, RUTHERFORD NJ, 07070. The medical research company can be reached via phone at 201-528-9200 or via email at [email protected]
MarketBeat Community Rating for Cancer Genetics (NASDAQ CGIX)
MarketBeat's community ratings are surveys of what our community members think about Cancer Genetics and other stocks. Vote "Outperform" if you believe CGIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
